Literature DB >> 11091269

Mapping of novel autoreactive epitopes of the diabetes-associated autoantigen IA-2.

J Seissler1, M Schott, N G Morgenthaler, W A Scherbaum.   

Abstract

IA-2, a member of the tyrosine phosphatase family, has been identified as a dominant autoantigen in type 1 diabetes. To define humoral IA-2 epitopes, we generated a panel of IA-2 deletion mutants and chimeric proteins using the highly homologous tyrosine phosphatase-like protein IA-2beta. Analysis of autoantibody reactivity in 111 IA-2 antibody positive sera from patients with type 1 diabetes revealed that humoral epitopes cluster to several domains of the intracytoplasmic part of IA-2 [IA-2ic, amino acid (aa) 604-979]. Immunodominant epitopes were found in the first N-terminal 73 amino acids (56% positive), in the middle domain residing between residues 699-874 (45% positive) and the C-terminus depending on the presence of aa 931-979 (at least 37% positive). Competition experiments with overlapping peptides revealed that autoantibody binding towards the N-terminus was dependent on residues 621-628. In the C-terminal domain, two novel conformation-dependent epitopes were identified. The first epitope requires the presence of the C-terminal part of IA-2 (aa 933-979) and an IA-2-specific region between residues 771-932. Reactivity against the second epitope was dependent on intact C-terminal domains as well as residues in the middle (aa 887-932) and N-terminal regions (aa 604-771) which are conserved in IA-2 and IA-2beta. We here defined novel autoantigenic determinants in the N-terminus of IA-2 and characterized conformational epitopes residing in the C-terminal region or spanning from C-terminal residues to the N-terminal domain of IA-2ic. The identification of dominant target regions of diabetes-specific autoantibodies may help to elucidate the molecular mechanisms involved in the autoimmunity towards IA-2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091269      PMCID: PMC1905775          DOI: 10.1046/j.1365-2249.2000.01352.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. The DENIS Study Group. Deutsche Nikotinamid Interventions-Studie.

Authors:  J Seissler; N G Morgenthaler; P Achenbach; E F Lampeter; D Glawe; M Payton; M Christie; W A Scherbaum
Journal:  Diabetologia       Date:  1996-11       Impact factor: 10.122

2.  Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen.

Authors:  V Lampasona; M Bearzatto; S Genovese; E Bosi; M Ferrari; E Bonifacio
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

3.  Autoantibodies to IA-2 in IDDM: location of major antigenic determinants.

Authors:  B Zhang; M S Lan; A L Notkins
Journal:  Diabetes       Date:  1997-01       Impact factor: 9.461

4.  GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives.

Authors:  J Dittler; D Seidel; M Schenker; A G Ziegler
Journal:  Diabetes       Date:  1998-04       Impact factor: 9.461

Review 5.  Immunology in diabetes: an update.

Authors:  D B Schranz; A Lernmark
Journal:  Diabetes Metab Rev       Date:  1998-03

6.  Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies.

Authors:  C F Verge; R Gianani; E Kawasaki; L Yu; M Pietropaolo; R A Jackson; H P Chase; G S Eisenbarth
Journal:  Diabetes       Date:  1996-07       Impact factor: 9.461

7.  IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens.

Authors:  E Bonifacio; V Lampasona; P J Bingley
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

8.  Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease.

Authors:  J Seissler; J J de Sonnaville; N G Morgenthaler; H Steinbrenner; D Glawe; U Y Khoo-Morgenthaler; M S Lan; A L Notkins; R J Heine; W A Scherbaum
Journal:  Diabetologia       Date:  1998-08       Impact factor: 10.122

9.  B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice.

Authors:  M Falcone; J Lee; G Patstone; B Yeung; N Sarvetnick
Journal:  J Immunol       Date:  1998-08-01       Impact factor: 5.422

10.  B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice.

Authors:  D V Serreze; H D Chapman; D S Varnum; M S Hanson; P C Reifsnyder; S D Richard; S A Fleming; E H Leiter; L D Shultz
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

View more
  2 in total

1.  Immunoreactivities Against Different Tyrosine-Phosphatase 2 (IA-2)(256-760) Protein Domains Characterize Distinct Phenotypes in Subjects With LADA.

Authors:  Claudio Tiberti; Luca D'Onofrio; Francesca Panimolle; Simona Zampetti; Ernesto Maddaloni; Raffaella Buzzetti
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-24       Impact factor: 6.055

2.  The core cysteines, (C909) of islet antigen-2 and (C945) of islet antigen-2β, are crucial to autoantibody binding in type 1 diabetes.

Authors:  Karen T Elvers; Ivey Geoghegan; Debbie K Shoemark; Vito Lampasona; Polly J Bingley; Alistair J K Williams
Journal:  Diabetes       Date:  2012-09-10       Impact factor: 9.461

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.